Connect with us

Press Releases

SECO 20/20 Expands Advanced Learning with New Formats

Focused on providing learning for every office member, sessions will provide actionable takeaways and business best practices.

mm

Published

on

(PRESS RELEASE) ATLANTA, GA — SECO 20/20, an annual conference providing the optometric profession with educational opportunities since 1923, has enriched its options for advanced learning. Launching at the 2020 conference, SECO will introduce diverse methods for idea sharing to support professionals to manage the changing landscape of clinical, technical and administrative healthcare. These enhancements include the addition of new programs, new learning formats, and a strategic MedPro360 initiative in collaboration with the Allied Ophthalmic Professionals committees, SECO’s commitment to education continues to be the foundation for the annual meeting.

“It is important that we continue to grow and evolve as an organization to meet the needs of our profession, our doctors, and all professionals working in the practice,” said Max Ernst, OD, President of SECO International, LLC. “We are proud of the caliber of education offered annually at SECO and we believe this next step will be instrumental in helping drive practices to the next level.”

Program Highlights:

Advanced Learning Courses: 80+ courses developed for technicians, opticians, paraoptometrics and office administrators. These Advanced Learning Courses will teach every member of an optometry office staff best practices for patient care, practice management, and business-related best practices.

Groundbreaking use of 3D Technology in the classroom: Optometric professionals will have the opportunity to learn and hear from world-renowned surgeon, Harvard’s John Miller, M.D, the latest surgical techniques using high definition, 3-D surgical videos.

MedPRO360 Practice Management: 34+ courses developed to deliver business intelligence and strategy resources for all eye care professionals. Led by optometric business gurus, the already sold out facilitated learning labs are designed to provide peer-to-peer sharing among office professionals.

Advertisement

Specs Buyer’s Certificate Program: 14+ hours of curated CE features interactive sessions on how to plan, purchase, promote and sell office frame inventory and drive marketing mix business decisions that will result in a profitable bottom line and loyal customers.

Allied Healthcare Professionals “New to the Office Series”: This new, 6+ hours series of sessions will focus on key topics including for Opticians and Technicians and Ocular Anatomy, Technician, Optical and Front Desk. This content will best serve new office staff and will provide tools and takeaways for cross-training office team members for efficiency.

The VIP “Bring Your Team” Experience at SECO 20/20: Register five or more members of your team to attend SECO 20/20, and SECO will extend a variety of exclusive benefits including a discounted registration. For offer, details visit AttendSECO.com.

New registration packages allow attendees to invest in their profession. Packages are customizable to fit any budget. More information can be found at AttendSECO.com. For more information and to register for the world’s largest continuing education conference for ophthalmic professionals set for March 4-8, 2020 in Atlanta, GA, visit AttendSECO.com.

Advertisement

SPONSORED VIDEO

SPONSORED BY KENMARK

Jump In — the Water’s Fine!

With a salute to summer’s shimmery, mermaid colors and warm weather-loving shades, Kenmark Eyewear celebrates this summer’s Aloha spirit with eyewear from Vera Wang, Kensie, Zac Posen and the Original Penguin Collection!

Promoted Headlines

Press Releases

First US Patient Gets Wireless Retinal Device Implant

It’s aimed at restoring partial sight to patients with advanced age-related macular degeneration.

mm

Published

on

(PRESS RELEASE) PITTSBURGH – UPMC has implanted the first patient in the U.S. with a new wireless retinal device as part of a clinical trial aimed at restoring partial sight to patients with advanced age-related macular degeneration.

“Vision research has advanced dramatically in the recent past and UPMC is at the forefront of this revolution. This is the first of many such breakthroughs led by UPMC and Pitt that will benefit patients with vision loss in our community and around the world,” said José-Alain Sahel, MD, director of the UPMC Eye Center, Eye and Ear Foundation chair of ophthalmology and distinguished professor at the University of Pittsburgh School of Medicine who initiated the trial at UPMC. “We are proud to be the first center in the United States to test this next generation retinal implant that could help treat an incurable disease like AMD.”

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?
INVISION Podcast

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?
INVISION Podcast

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries
INVISION Podcast

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries

The system, called PRIMA, is designed to restore sight in patients blinded by retinal degeneration. It consists of a 2 millimeter-by-2 millimeter, 30-micron thick miniaturized wireless photovoltaic chip placed under the damaged retina. It works in tandem with augmented reality glasses that have a built-in miniaturized camera and infrared projector.

The chip acts like a tiny artificial retina, made up of 378 tiny electrodes that convert infrared light from the glasses to electrical signals that are carried by the optic nerve to the brain. After receiving the implant, patients undergo an intensive rehabilitation program that trains their brains to understand and interpret the signals from the implant in combination with their remaining natural vision. Compared to earlier-generation implants, PRIMA is wireless and has significantly more electrodes, which allows for the transmission of more visual information.

“This is an incredibly exciting first for us at UPMC and I’m honored to be a part of it,” said Joseph Martel, MD, the implanting surgeon at the UPMC Eye Center and the Pitt School of Medicine, and the principal investigator of the trial at UPMC. “I’m grateful to our patients who have volunteered to participate in this trial, without whom this would not be possible.”

AMD is the leading cause of vision loss in people older than 50. Today, it affects approximately 14 million people in the United States, and the prevalence is expected to rise as the baby boomers age. As AMD progresses, the center of vision becomes increasingly blurry. “Atrophic” AMD, which accounts for a large proportion of advanced cases, has no curative treatment available.

The UPMC feasibility trial is running in parallel with the first-in-human trial in France, which involves five patients with advanced AMD, who now have been followed for more than a year. The 12-month results from the French study demonstrated the ability of most patients to identify sequences of letters and there were no device-related serious adverse effects.

“We are working with a great sense of urgency because the aging population of the United States, especially the western Pennsylvania region we live in, will see a significant rise in the number of patients at risk for vision loss through diseases like age-related macular degeneration, glaucoma and vascular eye disease, as well as earlier onset genetic conditions such as retinitis pigmentosa,” said Sahel. “This is why our physicians and researchers at UPMC and Pitt, in collaboration with our U.S. and international colleagues — especially at the Paris Vision Institute at Sorbonne University — are taking a multi-pronged effort to treat and rehabilitate patients with vision impairments.”

In March 2019, UPMC broke ground on the UPMC Vision and Rehabilitation Tower at UPMC Mercy, which when completed, will provide advanced specialty clinical care and innovative programs for visually impaired patients. It also will be the home for the vision research program at Pitt and UPMC.

The PRIMA implant was invented by Daniel Palanker, professor of ophthalmology at Stanford University, and licensed and developed by Pixium Vision, a spin-off from the Paris Vision Institute. Sahel is a co-founder of Pixium and holds shares in the company.

Continue Reading

Press Releases

There Might Be a Faster and Cheaper Way to Test for Myopia

The research comes from Flinders University in Australia.

mm

Published

on

(PRESS RELEASE) Myopia could become significantly easier to assess, according to a group of scientists.

Progressive research at Flinders University in Australia has identified a new method to measure how it affects the eye, a new article in PLOS ONE reveals.

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?
INVISION Podcast

Podcast: Is Eyecare in Canada Really More Like the US Than We Think?

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?
INVISION Podcast

Podcast: What Exactly Does it Take to Become America’s Finest Optical Retailer?

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries
INVISION Podcast

Podcast: Why Optical (and Especially Optical Retail) Is Lagging Behind Other Industries

The work was based on testing of 70 volunteers, with the Flinders ophthalmology and medical device research institute experts taking a novel approach with optical coherence tomography (OCT), a device already available in most optometric and all ophthalmic practices.

“Our work uses the OCT and finds irregularities at this scale that correlate with the size of the eye, and therefore the degree of myopia,” says eye specialist Dr. Stewart Lake, from Flinders University.

“This may help monitor, measure, and explore the effects of myopia and how it leads to vision loss,” he says, adding that further development could make the system suitable for use in regular clinical practice.

Prior research elsewhere with MRI scanning has demonstrated large scale irregularities in the eyeball in highly myopic eyes.

OCT can sample the shape of the eye on a much smaller scale than MRI. The OCT testing will be far cheaper, is more readily available and repeatable as a test, researchers say in the article.

Myopia (short or near-sightedness) is for many an inconvenience requiring glasses or contact lens to correct. However, globally it is an epidemic and a major cause of vision loss and sometimes blindness.

Myopia is defined practically by the strength of lens required to correct eyesight. It was already known that myopia relates strongly to the size/length of the eyeball.

Global estimates forecast up to 5 billion people will have myopia and 1 billion people could suffer with high myopia by 2050, placing a significant burden on health systems to manage and prevent myopia-related ocular complications and vision loss.

This seven-fold increase, between 2000 and 2050, would make myopia the leading cause of permanent blindness worldwide.

High myopia increases the risk of pathological ocular changes such as cataract, glaucoma, retinal detachment and myopic macular degeneration, all of which cause irreversible vision loss

Continue Reading

Press Releases

Prevent Blindness Promotes Glaucoma Awareness This Month

More than 3.2 million Americans ages 40 and over have the condition.

mm

Published

on

(PRESS RELEASE) CHICAGO – According to estimates from the Prevent Blindness report “Future of Vision: Forecasting the Prevalence and Costs of Vision Problems,” more than 3.2 million Americans ages 40 and over have glaucoma in the year 2020. The number is expected to increase as the population ages. Glaucoma, often referred to as the “the sneak thief of sight,” is a leading cause of vision loss that damages the optic nerve. Although symptoms may not be noticeable at first, glaucoma slowly diminishes peripheral vision, making activities such as driving increasingly difficult.

January is National Glaucoma Awareness Month and Prevent Blindness, the nation’s oldest volunteer eye health and safety nonprofit organization, seeks to educate the public on the disease, including risk factors, types of glaucoma, treatment options and more. Prevent Blindness offers a dedicated web page providing patients and their caregivers with free information at https://www.preventblindness.org/glaucoma or its online resource, Living Well with Low Vision at https://lowvision.preventblindness.org.

More women than men have glaucoma. Risk factors for glaucoma also include:

  • Age – The older you are, the greater you are at risk (especially those more than 60 years old).
  • Race – African-Americans age 40 and over are 4-5 times more likely to have glaucoma than others. Hispanics are also at increased risk for glaucoma as they age. Those of Asian and Native American descent are at increased risk for angle closure glaucoma.
  • Family History – If you have a direct relative with glaucoma, you are more likely to get glaucoma. If you are diagnosed with glaucoma, strongly encourage your family members to get complete eye exams.
  • Medical History – You are at higher risk if you have a history of high pressure in the eyes, previous eye injury, long term steroid use, or are farsighted or nearsighted.

The American Academy of Ophthalmology (AAO) also states that those with diabetes, migraines, high blood pressure, poor blood circulation or other health problems affecting the whole body are at increased risk of glaucoma.

“The year 2020 is an ideal reminder for all of us to make the resolution today to save our vision for tomorrow,” said Jeff Todd, president and CEO of Prevent Blindness. “By detecting vision problems and treating them early, including those from glaucoma, we can help to avoid significant vision impairment.”

Continue Reading

Advertisement

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Instagram

This error message is only visible to WordPress admins

Error: API requests are being delayed for this account. New posts will not be retrieved.

There may be an issue with the Instagram Access Token that you are using. Your server might also be unable to connect to Instagram at this time.

Error: No posts found.

Make sure this account has posts available on instagram.com.

Error: admin-ajax.php test was not successful. Some features may not be available.

Please visit this page to troubleshoot.

Most Popular